{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:13:28Z","timestamp":1772802808620,"version":"3.50.1"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T00:00:00Z","timestamp":1515110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0190497","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T14:00:48Z","timestamp":1515160848000},"page":"e0190497","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study"],"prefix":"10.1371","volume":"13","author":[{"given":"Chun-Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tseng-Hsi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chou-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-2203","authenticated-orcid":true,"given":"Chou-Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,1,5]]},"reference":[{"key":"ref1","first-page":"1688","article-title":"International trends in colorectal cancer incidence rates","volume":"18","author":"MM Center","year":"2009"},{"key":"ref2","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal. A Global cancer statistics, 2012. http:\/\/onlinelibrary.wiley.com\/doi\/10.3322\/caac.21262\/full<\/ext-link> (accessed Feb 12, 2017)"},{"key":"ref3","first-page":"145","article-title":"Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus","volume":"13","author":"AL Cheng","year":"2014"},{"key":"ref4","unstructured":"Taiwan Ministry of Health and welfare: malignant tumor: Incidence in Taiwan in 2012. http:\/\/www.mohw.gov.tw\/cht\/DOS\/Statistic.aspx?f_list_no=312&fod_list_no=5477<\/ext-link>, (accessed Feb 1, 2017)"},{"key":"ref5","first-page":"784","article-title":"Trends in colorectal cancer in the south of the Netherlands 1975\u20132007: rectal cancer survival levels with colon cancer survival","volume":"49","author":"V Lemmens","year":"2010"},{"key":"ref6","first-page":"2476","article-title":"Improving outcomes in colorectal cancer: where do we go from here?","volume":"49","author":"E Van Cutsem","year":"2013"},{"key":"ref7","first-page":"1408","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"E Van Cutsem","year":"2009"},{"key":"ref8","first-page":"1386","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"E Van Cutsem","year":"2016"},{"key":"ref9","first-page":"2013","article-title":"Bevacizumab in combination with Oxaliplatin-Based chemotherapy as first-Line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"LB Saltz","year":"2008"},{"key":"ref10","first-page":"1539","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200","volume":"25","author":"BJ Giantonio","year":"2007"},{"key":"ref11","first-page":"1757","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"CS Karapetis","year":"2008"},{"key":"ref12","first-page":"245","article-title":"Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal andoncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"SM Wilhelm","year":"2011"},{"key":"ref13","first-page":"303","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT): an international, multicentre, randomized, placebo controlled, phase 3 trial","volume":"381","author":"A Grothey","year":"2013"},{"key":"ref14","first-page":"619","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"J Li","year":"2015"},{"key":"ref15","first-page":"740","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulation","volume":"33","author":"T Yoshino","year":"2015"},{"issue":"3","key":"ref16","article-title":"Optimal use of Regorafenib: Dosing strategies and patient selection","volume":"14","author":"A Grothey","year":"2016"},{"issue":"8","key":"ref17","article-title":"Regorafenib in Metastatic colorectal cancer: Optimal dosing and patient selection recommendations","volume":"13","author":"A Grothey","year":"2015"},{"key":"ref18","first-page":"896","article-title":"FDA approves regorafenib(Stivarga) for metastatic colorectal cancer","volume":"26","year":"2012"},{"key":"ref19","unstructured":"National Health Insurance Administration, ministry of health and welfare payment for antineoplastic drugs 9.51. regorafenib. http:\/\/www.nhi.gov.tw\/Resource\/bulletin\/6449_1050035949-2.pdf<\/ext-link> (accessed Feb 12, 2017)."},{"key":"ref20","first-page":"337","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"D Cunningham","year":"2004"},{"key":"ref21","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 2.2016. https:\/\/www.tri-kobe.org\/nccn\/guideline\/colorectal\/english\/colon.pdf<\/ext-link> (accessed Feb 12, 2017)."},{"key":"ref22","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009"},{"key":"ref23","first-page":"1722","article-title":"Regorafenib (BAY 73\u20134506) in advanced colorectal cancer:a phase I study","volume":"106","author":"D Strumberg","year":"2012","journal-title":"B"},{"key":"ref24","first-page":"1","article-title":"Optimizing Treatment OutcomesWith Regorafenib: PersonalizedDosing and Other Strategies to Support Patient Care","volume":"19","author":"A Grothey","year":"2014"},{"issue":"9","key":"ref25","first-page":"2659","article-title":"A Phase I Dose\u2013Escalation Study of Regorafenib(BAY 73\u20134506), an Inhibitor of Oncogenic, Angiogenic, andStromal Kinases, in Patients with Advanced Solid Tumors","volume":"18","author":"K Mross","year":"2012"},{"key":"ref26","first-page":"1","article-title":"The real-world use of regorafenib for metastaticcolorectal cancer: multicentre analysis of treatmentpattern and outcomes in Hong Kong","volume":"0","author":"KO Lam","year":"2016"},{"key":"ref27","first-page":"1560","article-title":"Regorafenib in combination with FOLFOX or FOLFIRIas first- or second-line treatment of colorectal cancer:results of a multicenter, phase Ib study","volume":"24","author":"B Schultheis","year":"2013"},{"key":"ref28","first-page":"2143","article-title":"FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping","volume":"7","author":"CY Lu","year":"2014"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0190497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T01:33:42Z","timestamp":1540258422000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0190497"}},"subtitle":[],"editor":[{"given":"Ramon Andrade","family":"De Mello","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0190497","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,5]]}}}